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Abstract
Background: Parents’ attitudes and beliefs in vaccination are important to understand for 
shaping vaccine acceptance and demand interventions. Little research has focused on developing a 
validated scale to measure parents’ attitudes towards vaccinations in low and middle-income 
countries; Ghana provided an opportunity develop a caregiver vaccination attitudes scale (CVAS) 
validated against childhood vaccine compliance.
Methods: We conducted a cluster survey of 373 households with children aged 12–35 months of 
age from Northern Region, Ghana. Caregivers responded to 22 vaccination behavior and belief 
survey items and provided the child’s vaccination status. In exploratory factor analysis (EFA) to 
assess CVAS content validity, we used parallel analysis to guide the number of factors to extract 
and principal axis factor analysis for factor extraction. Reliability of the scale was assessed using 
McDonald’s Omega coefficient. Criterion validity of scale and subscales was assessed against 
receipt of vaccinations by 12 months of age and vaccination delay, using number of days 
undervaccinated.
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Results: EFA of CVAS responses resulted in removing 11 of 22 survey items due to loadings 
<0.30 and development of a 5-factor structure with subscales for Vaccine-Preventable Disease 
(VPD) Awareness, Vaccine Benefits, Past Behavior, Vaccine Efficacy and Safety, and Trust. The 5 
factors accounted for 69% of the common variance and omega coefficients were >0.73 for all 
subscales. Validity analysis indicated that for every unit increase in the parent’s scale score, the 
odds of the child being vaccinated decreased by 0.58 (95% confidence interval [CI]: 0.37,0.68) 
and the number of days under-vaccinated increased by 86 (95%CI: 28,143). The final 3-factor 
scale included Vaccine Benefits, Past Behavior, and Vaccine Efficacy and Safety.
Discussion: The final CVAS included three factors associated with vaccine compliance in 
Ghana, although several survey items suggested for use in vaccine acceptance scales were 
dropped. Replicating this study in several country settings will provide additional evidence to 
assist in refining a tool for use in routine vaccine acceptance and demand surveillance efforts.
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1. Introduction
Globally, childhood vaccination has contributed to a dramatic decline in morbidity and 
mortality associated with vaccine-preventable diseases (VPD). However, global coverage of 
the third dose of diphtheria-tetanus-pertussis containing vaccine (DTPcv3) has stalled in 
recent years, with concerns raised about the role of parents’ beliefs and attitudes about 
vaccination as a contributor [1–3]. To further drive vaccine acceptance and demand, interest 
has grown in developing methods to characterize parents’ vaccination beliefs and how they 
correlate and predict compliance to recommended childhood vaccinations [4,5]. These 
methods could be used in routine monitoring of specific parental knowledge, beliefs and 
attitudes about vaccination that are consistently correlated with vaccine compliance and for 
developing more targeted approaches to address parents’ concerns about vaccination 
correlated with vaccine compliance, i.e. the child’s vaccination status.
Multiple researchers in high-income country settings have developed psychometric scales 
designed to measure parents’ attitudes towards vaccination by categorizing attitudes into 
distinct areas of concern. In the United States and Canada, multiple scales to measure 
parental concerns about childhood vaccines and adolescent vaccines have been released 
since 2010, including the Vaccine Confidence Scale (VCS) to assess adolescent vaccination 
beliefs of US parents and the human papillomavirus (HPV) attitudes and beliefs scale 
(HABS) to assess HPV vaccination beliefs of Canadian parents [6–10]. In 2011, Opel and 
colleagues published the Parental Attitudes towards Childhood Vaccination scale (PACV) 
which has four psychometric domains: beliefs about vaccine safety and efficacy, 
immunization behavior, attitudes about vaccine mandates, and trust [11,12]. In 2012, the 
World Health Organization (WHO) convened a vaccine hesitancy working group which 
subsequently recommended researching and evaluating a series of survey items, largely 
based on the PACV, to determine if they could be used as the basis for a caregiver vaccine 
acceptance and demand scale adapted to low and middle-income country settings [4,13]. To 
properly understand if survey items from scales such as the PACV can be used in new 
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settings, a validation and reliability process should be undertaken to better understand the 
local parental belief structure about vaccinations and how these relate to vaccine compliance 
[14]. This validation and reliability process allows for the identification of specific parental 
attitudes about vaccination (as ascertained by identified survey items) which are consistently 
and reliably correlated to the child’s vaccination status. To date, few validated and reliable 
parental attitude about vaccination scales have been developed in low or middle-income 
country settings [15,16] and none have been developed in African settings, leaving a 
knowledge gap in validated tools to measure and understand the influence of parents’ 
vaccination-related attitudes, beliefs and knowledge on childhood vaccination outcomes in 
these settings. Additional, concern exists that rising numbers of caregivers in Africa may be 
delaying or refusing recommended vaccinations for their children and few tools to measure 
this vaccine hesitancy are available [17]. The WHO Strategic Advisory Group of Experts 
(SAGE) working group on vaccine hesitancy defined vaccine hesitancy as “delay in 
acceptance or refusal of vaccines despite availability of vaccination services. Vaccine 
hesitancy is complex and context specific, varying across time, place and vaccines. It is 
influenced by factors such as complacency, convenience and confidence” [13].
Studies in low- and middle-income country settings have highlighted caregivers’ concerns 
about vaccination, with variations across geographical and cultural settings. Such concerns 
include perceptions of harmful effects from vaccination, mistrust in vaccination programs, 
and fear of potential side effects from vaccination [2]. However, studies have not 
consistently identified associations between these concerns and the child’s vaccination 
status, although it is hypothesized that a caregiver’s hesitancy about vaccination can lead to 
vaccine delay and/or refusal. Creating a valid and reliable tool to monitor, screen and 
identify parents with concerns about vaccination that lead to vaccine delay and refusal, 
especially in LMICs, is a critical step for countries seeking to make evidence-based 
decisions about vaccine acceptance and demand creation strategies. Our objectives for this 
study were to assess the content validity of a scale designed to measure parents’ attitudes 
towards vaccination in Ghana, determine scale reliability, and evaluate concurrent criterion 
validity of the scale through two outcomes: child’s vaccination status by 12 months of age 
and child’s vaccination delay.
Ghana has had relatively high vaccination coverage (>85%) for infant vaccines since 2007. 
The country has also been at the forefront of vaccine introductions among African countries, 
having introduced pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and a second 
dose of measles-containing vaccine (MCV2) simultaneously in 2012. However, challenges 
are noted around the timeliness of vaccinations received, with up to 60% of infants receiving 
delayed vaccinations [18], leading to survey items about the determinants of vaccination 
delay in Ghana. Additionally, the country has experience challenges with reaching high 
vaccination coverage for vaccines provided to children in their second year of life [19], with 
a recent study noting the need to implemented targeted strategies promoting parental 
behavior change to strengthen coverage of all vaccines recommended in in Ghana, regardless 
of age. Another study of human papillomavirus (HPV) vaccination uptake in Ghana 
identified challenges with low perceived risk of disease, role of the parents (as opposed to 
the provider or government) as the primary decision-makers for vaccination of the child, and 
parental concern about side effects following vaccination. As part of a multi-partner effort to 
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further improve the Ghana immunization program, particularly for vaccines given beyond 
one year of age, Ghana Health Service (GHS) recognized the need to tailor its vaccine 
acceptance and demand promotion activities [19] to ensure both high and timely uptake of 
all vaccines. This initiative, detailed elsewhere [19], includes special efforts to catch children 
up on missed vaccines, increase timeliness of all recommended vaccinations, improve social 
mobilization efforts, tailor healthcare worker and caregiver interpersonal communications, 
and improve urban immunization strategies. The vaccine acceptance scale construction 
effort was housed within this multi-partner effort, with specific programmatic objectives of 
informing the design of future vaccine acceptance and demand promotion activities and 
evaluating the effect of these activities.
2. Methods
2.1. Scale development: identify measures
We followed a six-step process to develop the validated vaccine acceptance scale (see Fig. 
1). In the first step, an initial draft of the scale was collaboratively developed by a multi-
agency study team comprised of individuals from the US Centers for Disease Control and 
Prevention, Emory University, and Ghana Health Service (GHS). To identify the measures 
for the caregiver vaccine acceptance scale (CVAS) module in Ghana, we conducted a review 
of existing vaccination attitude scales and recommendations for measuring parental attitudes 
towards vaccination [4,6,11,12,20–28]. We also developed six de novo survey items based 
on discussions with immunization professionals who work on vaccine acceptance and 
demand interventions in African countries. In total, 22 survey items (10 of Likert scale 
format; 12 of Yes/no/Do not know format) were incorporated into an initial draft of the 
CVAS module (Table 1). A final iteration of the scale included input from caregiver focus 
group discussions and final reviews by GHS immunization program focal points.
The final 22 survey items included topics specific to caregiver perceptions of the combined 
benefits and drawbacks of vaccination, beliefs about illness versus vaccination, attitudes 
towards receipt of multiple injectable vaccinations in the same vaccination visit, community 
norms about vaccination, awareness and perceptions of vaccine safety, past experiences with 
vaccine-preventable diseases and vaccination services, and trust in the healthcare system 
(Table 1). Among the 14 survey items adapted from the PACV, the PACV domains covered 
included “beliefs about vaccine safety and efficacy”, ‘‘immunization behavior’, and ‘‘trust”.
2.2. Data collection: survey design and participants
To collect CVAS module data, we designed and implemented a cross-sectional, household-
based survey in Northern Region, Ghana. The primary intent of the survey was to estimate 
regional vaccination coverage as part of a multi-partner initiative to improve the coverage of 
childhood vaccinations in Ghana and is detailed elsewhere [19]; we incorporated our CVAS 
module into this survey. For the survey, we randomly selected 37 enumeration areas by 
probability proportional to size (PPS) sampling and then aimed to randomly select 10 
households with children aged 12–35 months within each enumeration area. The sampling 
yielded 373 households for assessment of the child’s vaccination history, sociodemographic 
characteristics, and parent’s vaccination beliefs via the CVAS module. All households 
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completed the CVAS module. The protocol was approved by the Ghana Health Services 
ethics review board, the CDC Human Subjects Office, and the Emory University 
Institutional Review Board.
2.3. Scale development: construct validity assessment
To evaluate construct validity, we used exploratory factor analysis (EFA) to analyze the 
Ghana dataset. Complete methodologic details for construct validity assessment are 
provided in the supplementary materials. In brief, in EFA, we used principal axis factor 
extraction (PAF) with a polychoric dispersion matrix, as this is recommended for analyzing 
ordinal data collected via Likert-type scales or variables that have few categories such as 
dichotomous items [29,30]. For factor rotations, we used promax, an oblique rotation, since 
we hypothesized some correlation between factors [31]. Exploratory factor analysis and 
reliability assessment were analyzed using a combination of the R psych package, MPlus 8, 
and FACTOR 10 software [32,33].
To determine the number of factors to extract, we used parallel analysis, very simple 
structure, scree plots, and proportion of variance explained methods. The final selection of 
number of factors to extract was based on review of the results from the latter methods 
alongside theoretical coherence of factors and simplicity of the factor loadings. Bentler’s 
simplicity index and the loading simplicity index were used to assess the level of factor 
loading simplicity, essentially a measure of how well each item loads onto a single factor 
versus multiple factors. To determine which items loaded onto each factor, we used a cutoff 
of 0.30. We tested the goodness of fit of the explanatory model using goodness of fit index 
(GFI), which ranges between 0 and 1, with values in excess of 0.9 considered an indication 
of adequate model fit.
2.4. Reliability assessment
To assess reliability/internal consistency of the derived factor solution, we examined 
Cronbach’s coefficient alpha and McDonald’s omega statistic. The omega statistic is 
preferable to use for skewed data and has been shown to be more robust than the alpha 
statistic for measuring closer to true reliability in these situations [34]. Additionally, the 
alpha statistic assumes equal factor loadings across items loading onto a factor to properly 
estimate the true reliability; if this is not the case, then alpha will underestimate reliability 
[35]. We also examined the Mislevy & Bock reliability estimate; further details provided in 
the supplemental materials.
2.5. Criterion validity assessment: vaccination outcomes
After the construct validity and reliability assessment steps yielded an initial version of a 
scale, single factor scale scores and an overall multi-factor scale score were calculated for 
each surveyed parent. A response for each survey item included in the scale was scored as 
either a 0 (non-hesitant response), 1 (partially hesitant response), or 2 (hesitant response). 
Survey items, which were negatively framed, were converted to the same direction scoring-
wise as items that were positively framed. For instance, the “Agree” response for the 
negatively worded item “Healthy children do not need immunizations” was scored as a ‘‘2”, 
whereas the “Disagree” response for the positively worded survey item ‘‘When a parent 
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refuses to vaccinate a child, it harms the entire community through risk of disease” was also 
scored as a ‘‘2”. Next, a parent’s responses to the survey items within a single factor were 
averaged to calculate the parent’s single factor scale score; this was done for each single 
factor scale include within the overall scale. Last, a parent’s total scale score was calculated 
by summing the parent’s separate single-factor scale scores together. The scale score was 
constructed so that the lowest scores were considered the least hesitant parents and the 
highest scores were the most hesitant parents.
To evaluate the relationship between parental attitudes and childhood vaccination outcomes, 
we used separate regression models to assess the association between the mean scale score 
and two separate outcomes: vaccination by 12 months of age and vaccination delay up to 12 
months of age. As indicated earlier, both vaccination receipt and vaccination delay are seen 
as key outcome measures associated with caregiver vaccine hesitancy and both outcomes 
have been used in the development of previous vaccine acceptance scales such as the PACV 
[9,11–13,36]. We used generalized estimating equation (GEE) models with a logit-link 
function to examine the association between the parental attitudes scale score (main 
exposure) and vaccination status as a dichotomous outcome (receipt of all vaccines 
recommended under 12 months of age, based on review of the child’s card or caregiver’s 
recall of vaccinations when the card was unavailable), as well as for receipt of measles-
containing vaccine 1st dose (MCV1) and DTPcv3 vaccines separately.
We used GEE models to examine vaccination delay as a continuous outcome for the 
combined series of MCV1, DTPcv 3-dose series, oral polio vaccine 3-dose series, rotavirus 
vaccine 2-dose series and pneumococcal conjugate vaccine 3-dose series, as well as for 
MCV1 and DTPcv3 vaccinations alone. Vaccination delay was defined as number of days 
under-vaccinated, per the method developed by Luman [37] and described in detail in 
supplementary materials. In brief, the number of days under-vaccinated was calculated by 
determining the age at which a child received each examined vaccine dose and comparing it 
to the recommended age (in days) based on the 2014–2016 Ghana vaccination schedule, 
accounting for minimum dose intervals and minimum eligible age (supplemental Table S1).
To explore the influence of each scale factor, we re-ran the non-vaccination and vaccination 
delay outcome models using each factor. Models controlled for the following demographic 
factors that prior research indicates are associated with under-vaccination in Ghana and 
elsewhere: mother’s age, mother’s education level, child’s gender, and child’s birth order 
[38]. Due to the clustered survey design, we accounted for the primary sampling unit as a 
repeated effect in the GEE models. In our modeling analyses conducted using SAS 9.3, we 
report the frequencies, means, percentages and odds ratios with 95% confidence intervals.
3. Results
3.1 Sample characteristics
There were 373 parent-child pairs surveyed. Detailed descriptive results are found in the 
supplementary materials. In brief, among caregivers, 371 (99%) indicated receipt of at least 
1 vaccination for the child and 353 (95%) of children had vaccination cards (Supplemental 
Table S2). For analysis of vaccination delay, multiple records were excluded due to lack of 
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sufficient information on vaccination dates (missing day, month, and/or year data). Of the 
373 records, 279 (75%) were usable for the vaccination delay analysis across all vaccine 
doses, 344 records (92%) for DTPcv3 vaccination delay, and 353 (95%) for MCV1 
vaccination delay.
Children of mothers who did not attend school were less likely than children of mothers with 
primary or secondary educational attainment to receive DTPcv3 vaccination (88% versus 
92% and 98%, respectively). Similarly, children of parents following a Traditionalist religion 
were less likely than Christian and Muslims to have received DTPcv3 vaccination (81% 
versus 92% and 90%, respectively). Firstborn children were slightly more likely to have 
received DTPcv3 versus later-born children (93% versus 90%), as were female children 
compared to male children (93% versus 88%).
3.2. Scale survey item descriptive results
Among interviewed caregivers, 20% indicated they had seen an individual with either polio, 
pneumonia, measles or whooping cough and 13% knew of someone in their family or 
community who had one of the latter diseases. Nearly all (99%) knew the location of 
vaccination and days/times of vaccination (94%) (Supplemental Table S3). Nearly all 
believed vaccines to be safe (97%), although 22% indicated that people in their community 
had expressed concerns possible side effects from vaccination. Although nearly all (97%) 
believed that following a nationally recommended vaccination schedule is a good idea and 
96% would want to have any future children get all recommended vaccinations, 22% and 
15% had indicated either ever delaying or ever deciding not to have a child receive a 
vaccination for reasons other than illness or allergy. A sizeable minority (23%) believed that 
healthy children did not need immunizations and expressed concerns about the number of 
vaccinations provided; with 41% agreeing that children get more vaccinations than are good 
for them and 23% disagreeing that children should get two injectable vaccinations in one 
visit rather than one per visit. Further descriptive details are provided in the supplemental 
materials.
3.3 Factor analysis
The distribution of scale items was examined visually using histograms and multivariate 
tests for skewness and kurtosis were conducted. One variable was dropped due to lack of 
sufficient data for each response category. There was evidence of asymmetry: values for 
skewness were >|1| for 14 items, and excess kurtosis was found for 16 items. The 
multivariate test of skewness was not statistically significant (p = 1.00), but the test of 
kurtosis was significant (P< 0.0001), further indicating the need to use a polychoric 
correlation matrix for EFA. Sampling adequacy tests indicated suitability of the data for EFA 
as the KMO measure of sampling adequacy was 0.58 and Bartlett’s test of sphericity was 
statistically significant (X2 = 749.9, P < 0.0001).
The results from parallel analysis using MRFA extraction and polychoric correlation 
suggested extraction of six factors from the dataset. Very simple structure analysis, using 
PAF extraction, polychoric correlation and promax rotation all suggested extraction of five 
factors. Visual assessment of the scree plot suggested extraction of between four and six 
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factors, and the Kaiser Criterion method resulted in three eigenvalues above 1.00, indicating 
suggested extraction of three factors. We chose to run EFA with models that had four, five 
and six factors extracted.
The 5-factor model included 11 items, with two loadings per factor for all except the fifth 
which had three items load greater than 0.30 (Table 2). The 4-factor model included the 
same first four factors and same eight items loading onto each factor. A 6-factor model 
included a factor where only one item loaded greater than 0.30. Based on the items that 
loaded onto each factor in the 5-factor model, we chose to name the factors as: VPD 
Awareness, Vaccine Benefits, Past Behavior, Efficacy and Safety, and Trust. The 4-factor 
model excluded the Trust factor.
3.4. Model fit, simplicity and reliability
The goodness of fit index value of 0.90 for the selected 5-factor model indicated an 
acceptable model fit. Bentler’s simplicity index value (0.96) and loading simplicity index 
(0.93) both indicated the 5-factor model to be an acceptable structural solution.
Mislevy and Bock reliability estimates for all five factors were >0.73; the factor, or subscale, 
with the lowest reliability was trust (Table 2). McDonald’s omega coefficients showed 
similar values, all >0.78. Cronbach’s alpha coefficients were >0.60 for the VPD Awareness, 
Vaccine Benefits and Past Behavior subscales; the coefficient for Efficacy and Safety was 
0.54 and for Trust was 0.41. Dropping any items from the Trust subscale failed to improve 
any internal reliability measures.
3.5. Criterion validation analysis: vaccination receipt
A one-point increase in a caregiver’s full scale score was associated with an odds ratio of 
0.58 (95% confidence interval [Cl]: 0.41, 0.80) for the odds of a child receiving a DTPcv3 
vaccination, indicating decreased likelihood of DTPcv3 vaccination as a caregiver’s full 
scale score increased (Table 3, Fig. S3). In separate analysis of each subscale, the Benefits 
domain showed the strongest association (odds ratio [OR]: 0.09; 95% CI: 0.02,0.39) whereas 
VPD Awareness showed the weakest association (OR: 0.94; 95% CI: 0.54,1.64) with 
DTPcv3 vaccination. Trust also showed a null association, even though the OR point 
estimate was far from the null (OR: 0.43; 95% CI: 0.07, 2.38). Receipt of MCV1 and of all 
vaccines showed similar patterns as those reported for DTPcv3 receipt (Supplemental Table 
S4). Four-factor and three-factor scales, which did not include the VPD Awareness domain 
(dropped in both) or the Trust domain (dropped in 3-factor scale only) showed stronger 
associations with the odds of receipt of each assessed vaccination outcome compared to the 
5-factor scale (Table 3).
3.6. Criterion validation analysis: vaccination delay
For every 1 point gain in a caregiver’s complete scale score, children were 11.1 (95% CI: 
3.7, 18.4) more days under-vaccinated for DTPcv3 compared to children who received a 
timely DTPcv3 vaccination (Table 4, Fig. S4). In separate analysis of each subscale, the 
Benefits domain showed the strongest association (101.0 days undervaccinated; 95% CI: 
51.3, 150.6) whereas VPD Awareness showed the weakest association (–1.0 days 
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undervaccinated; 95% CI: –12.9,10.8). Past Behavior and Trust also showed a null 
association. For every 1 point gain in the caregiver’s complete scale score, children were 5.6 
(95% CI: 2.2, 8.9) more days undervaccinated for MCV1 compared to children who 
received timely MCV1 vaccination (Supplemental Table S5). Separate subscale analyses 
indicated association between days undervaccinated for MCV1 and VPD Awareness. Days 
undervaccinated for all vaccines showed associations with the Vaccine Benefits, Past 
Behavior and Efficacy and Safety domains and null associations for VPD Awareness and 
Trust.
3.7. Characteristics of recommended scale
The 3-factor scale with six items that included Benefits, Past Behavior, and Vaccine Efficacy 
and Safety domains showed the most consistency in terms of significance of subscale 
associations with assessed vaccination outcomes (Tables S3 and S4). Mislevy and Bock 
reliability estimates and omega coefficients were >0.80 for the three factors in this scale and 
factor loadings were ≥0.45 for all six items.
4. Discussion
In our study of Ghanaian parents of children aged 12–35 months, we were able to develop a 
contextually valid and internally reliable scale for parental attitudes and beliefs towards 
vaccination and this scale score was highly associated with the child’s vaccination status and 
number of days undervaccinated. The psychometric domain, Vaccine Benefits, showed a 
strong association with the two evaluated vaccination outcome indicators, and could be the 
basis for a short-form (single factor) scale. We identified one new domain not seen in 
previous scales, VPD Awareness, which may be unique to settings where VPDs are still 
commonly seen in the community; however, it was not associated with most vaccination 
outcome indicators. Several items proposed used in other high-income country-based scales 
failed to load onto any factors in this setting, but replicating such research will help further 
inform recommendations for use of these items.
In comparison to other scales for assessing parental attitudes towards childhood vaccination, 
four out of five of the CVAS domains showed similarities with the domain structures of the 
vaccine confidence scale (VCS) and the parental attitudes towards childhood vaccines scale 
(PACV). The VCS was developed using existing behavioral survey items inserted into the 
US national immunization survey, whereas the PACV was developed from review of 
previous parent attitude and belief surveys in the US and then through data collected from a 
convenience survey in Seattle, Washington. The two items in the CVAS beliefs domain 
closely overlap two of the items that comprise the beliefs domain in the vaccine confidence 
scale (VCS), although one of the items in the CVAS vaccine efficacy and safety domain is 
also listed in the beliefs domain of the VCS [6,26]. The two items in the CVAS vaccine 
efficacy and safety domain are derived from the same domain found in the PACV scale [36]. 
In our scale, we did face challenges in naming the Vaccine Benefits domain and the Efficacy 
and Safety domain as the items within each generally appear to overlap from a wording 
perspective. However, we chose not to eliminate either domain or merge them as none of our 
factor analyses indicated that these items all loaded onto the same factor. Additionally, from 
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a wording perspective, key differences exist, as both items in the Vaccine Benefits domain 
start with “I believe...” and were Yes/No/Don’t know formats, whereas the two items in the 
Efficacy and Safety domain were statements using a Likert scale format. Lastly, our two 
VPD Awareness domain items are de novo, although they have overlap to items in the 
threats domain of a Canada-based HPV attitudes and beliefs scale [10].
Our findings in Ghana reflect both similarities and differences in scales developed in the 
United States (US). Our overall scale score was associated with both child’s vaccination 
receipt and vaccination delay, while three of five factors were consistently associated with 
both of receipt and delay. In the PACV study, originally developed in an urban setting of the 
US, the overall scale was also associated with vaccination delay [12], although, in an 
adapted version of the PACV for adolescent vaccinations in the United States, the two-
domain scale score was not associated with vaccination receipt [9]. Analyses of the vaccine 
confidence scale (VCS), also developed in the US, indicated that the overall score was 
associated with vaccination receipt, but only one of the three VCS domains was associated 
with delay [26,39]. Similar to our finding in Ghana that the Trust domain was not associated 
with vaccination outcomes, the VCS also reported that the Trust domain was not associated 
with vaccination refusal, status or delay in a US-based population [39]. In our Ghana study, 
the lack of a strong relationship between the Trust domain and the immunization outcomes 
was surprising, considering that the Trust domain is described as a core component of 
caregiver vaccine confidence, defined by the WHO vaccine hesitancy working group as: 
“trust in vaccine safety, the system that delivers vaccines, and the policymakers who 
recommend vaccinations” [40]. In our Ghana survey, nearly all participants stated high 
levels of trust in healthcare providers and government-recommended vaccination schedule, 
per responses to our Trust domain survey items. We hypothesize that the weak relationship 
in our Ghana survey results could be due to either the selection of Trust survey items that 
failed to sufficiently dichotomize between low trust and high trust individuals or to the Trust 
being so universally high that it failed to be a key hurdle to vaccine compliance in this high 
compliance population. Future research on the latter hypothesis would help with better 
understanding this situation.
The identification of the VPD Awareness domain in our Ghana scale was unique from 
previously published scales developed in high-income country settings and this may be due, 
in part, to the different context within which we developed this scale compared to these 
previously developed scales. Both items in this domain ask about a caregiver’s experience 
with VPDs; we developed these items on the basis of the availability heuristic, which is used 
in the context of vaccinations to describe how a caregiver perceives the probability of a 
vaccine-preventable infection based upon the availability/ease of recalling relevant past 
examples [41]. In Ghana, however, because vaccination coverage has been high for several 
years, most VPDs are relatively uncommon. Future research may consider including similar 
VPD Awareness items to assess their criterion validity in settings with higher VPD burden. 
The differences in scale structure, such as the VPD awareness domain, for Ghana compared 
to scales developed in previous high-income country settings indicate the importance of 
implementing a scale development process in settings that one considers to be quite different 
from the settings where similar scales have been developed [14,42]. By identifying the 
importance of the VPD awareness domain in Ghana, which would not have been identified if 
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previously developed scales such as the PACV were directly used illustrates the importance 
of this tailored scale development work, rather than using an existing scale which would not 
have identified the existence and importance of this factor. The GHS immunization program 
team is able to make use of these findings in a variety of ways.
The planned use of the validated scale in Ghana provides an example of its practical 
applications from the viewpoint of an immunization program manager. The identification of 
specific parental attitudes about vaccination that were and were not correlated with vaccine 
compliance is being used in the planning for tailored health worker trainings designed to 
improve vaccine acceptance and demand in low-coverage areas of the country. These 
trainings focused on methods to improve interpersonal communications between the 
healthcare provider and the caregiver; thus the specific communication topics covered in the 
trainings were tailored towards the findings from the scale around addressing caregivers’ 
concerns about vaccine safety, their perceptions of the efficacy of vaccination, and 
understanding how previous vaccination and vaccine-preventable disease experiences can 
play a role in how caregivers perceive the importance of childhood vaccination. 
Additionally, the validated scale will be used as an evaluation tool for a series of vaccine 
acceptance and demand promotion activities designed to improve caregiver attitudes towards 
vaccination. Specifically, in the evaluation of these vaccine acceptance and demand 
promotion activities, parents will be surveyed before and after activity implementation to 
calculate pre and post-scale scores for parents and pre-post scale score differences will be 
examined for statistical significance using regression modeling techniques. Lastly, in future 
household health surveys, the scale will be incorporated to allow for measuring these 
caregiver attitudes that have shown consistent correlations with vaccine compliance in 
Ghana, thus providing an opportunity to assess attitude trends over time.
Replicating scale development in other settings is highly desirable to ensure a fuller picture 
of how such scales may need to vary in domain structure and item specification. Generally, 
when a scale is used in a population that differs from the one where it was initially validated, 
then both the validity and reliability should be checked again to ensure it maintains its 
psychometric properties [14,42]. In particular the use of the scale in a new setting will likely 
include translation to a new language, which can alter the psychometric qualities of the scale 
[14,42]. This process of scale assessment in a new setting can use other methods beyond 
EFA, including confirmatory factor analysis, item response theory, or related methodologies 
to examine scale validity and reliability to re-examine the psychometric properties. The 
psychometric differences that emerge across scales validated in different settings can provide 
important methodological conclusions (i.e. it may not be feasible to use a single scale across 
countries). In Ghana, for instance, we developed our scale by starting with survey items 
derived from scales used in high-income countries or suggested for global use [4]. However, 
a systematic review of studies conducted to assess caregiver attitudes and beliefs towards 
vaccination in LMICs would be useful to generate a new listing of possible scale items. 
Additionally, future research should incorporate a prospective study whereby the predictive 
criterion validity of this scale is assessed. After further validation, consideration may be 
given for incorporating the scale into routine local household surveys to allow for ongoing 
vaccine hesitancy surveillance.
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Our study is subject to limitations. The survey was cross-sectional, so information for the 
scale and for vaccination status was collected at the same time; thus our criterion validity 
was limited to concurrent rather than predictive validity. Our sample size was sufficient for 
EFA, but we could not split the sample into two sets to also do confirmatory factor analysis, 
which could have further strengthened our results. For the vaccination status outcome, we 
did incorporate both card-based and caregiver recall information so we could utilize the 
entire dataset, and caregiver recall could have resulted in some misclassification of 
vaccination status. However, card retention was very high (data for only 20/373 children 
relied on recall-based information) and in a sub-analysis, vaccination status of children with 
only recall-based information did not differ from children with card-based information. 
Lastly, we originally planned to use a 5-level Likert scale for Likert-formatted survey items 
which could have provided more precision on agreement level for respondents. However in a 
formative evaluation of these survey items in Ghana and similar settings, respondents 
generally found 5-level Likert items to be difficult to understand, compared to the 3-level 
design.
Understanding the caregivers’ beliefs and attitudes that drive acceptance of childhood 
vaccination is critical for the success of any immunization program. Our study is the first to 
document development of a valid and reliable scale to assess caregiver attitudes and beliefs 
towards vaccination in a low- or middle- income country setting and show a high level of 
association of the scale score with child’s vaccination status. Continued development of 
these types of tools is increasingly important for both understanding and monitoring vaccine 
confidence trends, and facilitating effective response, so that the greatest number of children 
receive the benefits from vaccination.
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Fig. 1. 
Flowchart of methodology used to develop the caregiver vaccination attitudes scale and key 
outcomes of each step, Ghana 2017.
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